Taurus 2 Trial

Trial Aim Description

Taurus 2 is a phase 2 trial using low intensity Magnetic Brain Stimulation (MBS). This trial is measuring the effects of magnetic brain stimulation (MBS for short) on Multiple Sclerosis (MS) symptoms. MBS can non-invasively and painlessly activate nerve cells in the human brain and can be used to change nerve cell activity. MBS is currently used to treat depression but has only been used for MS in the research setting.

Inclusion Criteria

• Age 18-65 (inclusive)
  (ii) Diagnosed with MS by an MS neurologist (McDonald criteria 2018)
  (iii) Stable and relapse-free for 6 months (either on or off MS treatment)
  (iv) Extended Disability Status Scale (EDSS) between 1.5 and 6 (inclusive)
  (v) Willing to travel to the site every weekday for 4 consecutive weeks
  (vi) Capacity to provide informed consent
  (vii) Access to the internet

Professor Allan Kermode is the Principal Investigator for this trial.